Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18939042 | 0.99 | DGAT1 (0.33) | DGAT1DAOTP53RAB9A | |
| SCHEMBL18939133 | 0.82 | ITGB3 (0.32) | — | |
| SCHEMBL18960799 | 0.81 | DGAT1 (0.42) | DGAT1TP53 | |
| Hydrochloric Acid SCHEMBL18939008 | 0.80 | DGAT1 (0.41) | DGAT1TP53 | |
| SCHEMBL18938989 | 0.79 | TP53 (0.32) | DAOTP53RAB9A | |
| Hydrochloric Acid SCHEMBL28658579 | 0.76 | TNIK (0.35) | DAOTP53RAB9A | |
| SCHEMBL28658267 | 0.75 | DAO (0.32) | DAO | |
| Hydrochloric Acid SCHEMBL18939177 | 0.74 | KDR (0.38) | DGAT1 | |
| SCHEMBL9299345 | 0.67 | ALDH1A1 (0.43) | — | |
| SCHEMBL18960806 | 0.65 | PDE4D (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48097-E1 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2020-07-14 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | CEP170, AADAC, NAA50 | DGAT1 4394/4885DAO 127/4885TP53 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.